[{"address1": "47 Hulfish Street", "city": "Princeton", "state": "NJ", "zip": "08542", "country": "United States", "phone": "609 662 2000", "fax": "609 662 2001", "website": "https://amicusrx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bradley L. Campbell M.B.A.", "age": 47, "title": "CEO, President & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1444183, "exercisedValue": 1306271, "unexercisedValue": 4951980}, {"maxAge": 1, "name": "Mr. Simon Nicolas Reade Harford", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 573057, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen S. Rosenberg", "age": 60, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 896294, "exercisedValue": 309811, "unexercisedValue": 2394883}, {"maxAge": 1, "name": "Mr. David M. Clark", "age": 47, "title": "Chief People Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 849242, "exercisedValue": 0, "unexercisedValue": 957810}, {"maxAge": 1, "name": "Dr. Jeffrey P. Castelli Ph.D.", "age": 51, "title": "Chief Development Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 855863, "exercisedValue": 0, "unexercisedValue": 1293086}, {"maxAge": 1, "name": "Ms. Samantha  Prout", "age": 45, "title": "Chief Accounting Officer & Controller", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jill  Weimer Ph.D.", "title": "Chief Science Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Andrew  Faughnan", "title": "Senior Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrik S. Florencio Esq.", "title": "Global Chief Compliance & Risk Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Diana  Moore", "title": "Head of Global Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 4, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.52, "open": 11.59, "dayLow": 11.29, "dayHigh": 11.735, "regularMarketPreviousClose": 11.52, "regularMarketOpen": 11.59, "regularMarketDayLow": 11.29, "regularMarketDayHigh": 11.735, "beta": 0.688, "forwardPE": 53.13636, "volume": 1472732, "regularMarketVolume": 1472732, "averageVolume": 2636643, "averageVolume10days": 2058140, "averageDailyVolume10Day": 2058140, "bid": 11.68, "ask": 11.71, "bidSize": 800, "askSize": 1000, "marketCap": 3467148800, "fiftyTwoWeekLow": 9.02, "fiftyTwoWeekHigh": 14.57, "priceToSalesTrailing12Months": 7.6091533, "fiftyDayAverage": 10.7116, "twoHundredDayAverage": 11.40435, "currency": "USD", "enterpriseValue": 3600723456, "profitMargins": -0.26233998, "floatShares": 238862472, "sharesOutstanding": 296591008, "sharesShort": 24042394, "sharesShortPriorMonth": 25861247, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.081099994, "heldPercentInsiders": 0.0074199997, "heldPercentInstitutions": 1.0773101, "shortRatio": 7.08, "shortPercentOfFloat": 0.081499994, "bookValue": 0.447, "priceToBook": 26.152124, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -119536000, "trailingEps": -0.39, "forwardEps": 0.22, "pegRatio": 0.41, "enterpriseToRevenue": 7.902, "enterpriseToEbitda": -215.832, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "FOLD", "underlyingSymbol": "FOLD", "shortName": "Amicus Therapeutics, Inc.", "longName": "Amicus Therapeutics, Inc.", "firstTradeDateEpochUtc": 1180618200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "18ecfd93-9817-3a94-a13a-c6019ef27903", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.69, "targetHighPrice": 20.0, "targetLowPrice": 13.0, "targetMeanPrice": 17.3, "targetMedianPrice": 18.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 260062000, "totalCashPerShare": 0.877, "ebitda": -16683000, "totalDebt": 444057984, "quickRatio": 2.054, "currentRatio": 2.747, "totalRevenue": 455655008, "debtToEquity": 335.08, "revenuePerShare": 1.515, "returnOnAssets": -0.02148, "returnOnEquity": -0.97939, "freeCashflow": 12992250, "operatingCashflow": -41893000, "revenueGrowth": 0.34, "grossMargins": 0.89883006, "ebitdaMargins": -0.03661, "operatingMargins": 0.11816, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]